Ezrin, radixin, and moesin are phosphorylated in response to 2-methoxyestradiol and modulate endothelial hyperpermeability

American Journal of Respiratory Cell and Molecular Biology

Volumn 45, Issue 6, 2011, Pages 1185-1194

  Bogatcheva, Natalia V ^a   Zemskova, Marina A ^a   Gorshkov, Boris A ^a   Kim, Kyung Mi ^a   Daglis, Gregory A ^a   Poirier, Christophe ^a   Verin, Alexander D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

2 methoxyestradiol; Barrier dysfunction; ERM; Phosphorylation; PKC

Indexed keywords

2 METHOXYESTRADIOL; EZRIN; F ACTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MOESIN; PACLITAXEL; PROTEIN KINASE C; RADIXIN; SMALL INTERFERING RNA;

ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; LUNG BLOOD VESSEL; MALE; MICROTUBULE; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY;

ANIMALS; CAPILLARY PERMEABILITY; CELLS, CULTURED; CYTOSKELETAL PROTEINS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ENZYME INHIBITORS; ESTRADIOL; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; MALE; MALEIMIDES; MEMBRANE PROTEINS; MICE; MICROFILAMENT PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; PHOSPHORYLATION; PROTEIN KINASE C; PYRROLES; RHO-ASSOCIATED KINASES; TUBULIN MODULATORS;

EID: 82755165225     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2011-0092OC     Document Type: Article

References (46)

1. Sutherland TE, Anderson RL, Hughes RA, Altmann E, Schuliga M, Ziogas J, Stewart AG. 2-methoxyestradiol: a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents. Drug Discov Today 2007;12:577-584. (Pubitemid 47031662)
2. Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, et al. A Phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 2005;11:6625-6633. (Pubitemid 41339003)
3. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 2006;5:22-27. (Pubitemid 43234973)
4. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2007;25:41-48. (Pubitemid 44657641)
5. Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, Schlossman R, Sidor CF, Anderson KC, Gertz MA. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res 2007;13:6162-6167. (Pubitemid 350075076)
6. Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C. Activity of 2 methoxyestradiol (panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 2009;115:90-96.
7. Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G. Phase I trial of 2-methoxyestradiol nanocrystal dispersion in advanced solid malignancies. Clin Cancer Res 2009;15:1460-1465.
8. Foster PA, Ho YT, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A. STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells. Anticancer Res 2009;29: 3751-3757.
9. Newman SP, Foster PA, Ho YT, Day JM, Raobaikady B, Kasprzyk PG, Leese MP, Potter BV, Reed MJ, Purohit A. The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. Br J Cancer 2007;97:1673-1682. (Pubitemid 350249364)
10. Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde JG, Lassalle M, Prevost G, Leese MP, Potter BV, et al. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res 2008;14:597-606. (Pubitemid 351226130)
11. Parsons MF, Foster PA, Chander SK, Jhalli R, Newman SP, Leese MP, Potter BV, Purohit A, Reed MJ. The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer. Br J Cancer 2008;99:1433-1441.
12. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994;91:3964-3968. (Pubitemid 24139553)
13. Birukova AA, Birukov KG, Gorshkov B, Liu F, Garcia JG, Verin AD. MAP kinases in lung endothelial permeability induced by microtubule disassembly. Am J Physiol Lung Cell Mol Physiol 2005;289:L75-L84. (Pubitemid 40863557)
14. Birukova AA, Smurova K, Birukov KG, Usatyuk P, Liu F, Kaibuchi K, Ricks-Cord A, Natarajan V, Alieva I, Garcia JG, et al. Microtubule disassembly induces cytoskeletal remodeling and lung vascular barrier dysfunction: role of Rho-dependent mechanisms. J Cell Physiol 2004;201:55-70. (Pubitemid 39187045)
15. Verin AD, Birukova A,Wang P, Liu F, Becker P, Birukov K, Garcia JG. Microtubule disassembly increases endothelial cell barrier dysfunction: role of MLC phosphorylation. Am J Physiol Lung Cell Mol Physiol 2001;281:L565-L574.
16. Bogatcheva NV, Adyshev D, Mambetsariev B, Moldobaeva N, Verin AD. Involvement of microtubules, p38, and Rho kinases pathway in 2-methoxyestradiol-induced lung vascular barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2007;292:L487-L499.
17. Koss M, Pfeiffer GR II, Wang Y, Thomas ST, Yerukhimovich M, Gaarde WA, Doerschuk CM, Wang Q. Ezrin/radixin/moesin proteins are phosphorylated by TNF-alpha and modulate permeability increases in human pulmonary microvascular endothelial cells. J Immunol 2006;176:1218-1227. (Pubitemid 43099726)
18. Csortos C, Czikora I, Bogatcheva NV, Adyshev DM, Poirier C, Olah G, Verin AD. TIMAP is a positive regulator of pulmonary endothelial barrier function. Am J Physiol Lung Cell Mol Physiol 2008;295:L440-L450.
19. Guo X, Wang L, Chen B, Li Q, Wang J, Zhao M, Wu W, Zhu P, Huang X, Huang Q. ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability. Am J Physiol Heart Circ Physiol 2009;297:H238-H246.
20. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010;11:276-287.
21. Gary R, Bretscher A. Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell 1995;6:1061-1075.
22. Nakamura F, Amieva MR, Furthmayr H. Phosphorylation of threonine 558 in the carboxyl-terminal actin-binding domain of moesin by thrombin activation of human platelets. J Biol Chem 1995;270:31377-31385. (Pubitemid 26012231)
23. Yonemura S, Matsui T, Tsukita S. Rho-dependent and-independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo. J Cell Sci 2002;115:2569-2580. (Pubitemid 34778074)
24. Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 1998;140:647-657. (Pubitemid 28134067)
25. Fievet BT, Gautreau A, Roy C, Del Maestro L, Mangeat P, Louvard D, Arpin M. Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol 2004;164:653-659. (Pubitemid 38282949)
26. Ng T, Parsons M, Hughes WE, Monypenny J, Zicha D, Gautreau A, Arpin M, Gschmeissner S, Verveer PJ, Bastiaens PI, et al. Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J 2001;20:2723-2741. (Pubitemid 32938557)
27. Pietromonaco SF, Simons PC, Altman A, Elias L. Protein kinase C-theta phosphorylation of moesin in the actin-binding sequence. J Biol Chem 1998;273:7594-7603. (Pubitemid 28153699)
28. Moitra J, Sammani S, Garcia JG. Re-evaluation of Evans blue dye as a marker of albumin clearance in murine models of acute lung injury. Transl Res 2007;150:253-265. (Pubitemid 47444609)
29. Wilkinson SE, Parker PJ, Nixon JS. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J 1993;294:335-337. (Pubitemid 23268828)
30. Moldobaeva A,Welsh-Servinsky LE, Shimoda LA, Stephens RS, Verin AD, Tuder RM, Pearse DB. Role of protein kinase G in barrier-protective effects of CGMP in human pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 2006;290:L919-L930. (Pubitemid 43725054)
31. Guo M, Breslin JW, Wu MH, Gottardi CJ, Yuan SY. VE-cadherin and beta-catenin binding dynamics during histamine-induced endothelial hyperpermeability. Am J Physiol Cell Physiol 2008;294:C977-C984. (Pubitemid 351507915)
32. Meiring JJ, Borm PJ, Bagate K, Semmler M, Seitz J, Takenaka S, Kreyling WG. The influence of hydrogen peroxide and histamine on lung permeability and translocation of iridium nanoparticles in the isolated perfused rat lung. Part Fibre Toxicol 2005;2:3.
33. Walkenstein MD, Peterson BT, Gerber JE, Hyde RW. Histamineinduced pulmonary edema distal to pulmonary arterial occlusion. J Appl Physiol 1985;58:1092-1098. (Pubitemid 15033218)
34. Nemmar A, Hamoir J, Nemery B, Gustin P. Evaluation of particle translocation across the alveolo-capillary barrier in isolated perfused rabbit lung model. Toxicology 2005;208:105-113. (Pubitemid 40143331)
35. Bogatcheva NV, Verin AD. The role of cytoskeleton in the regulation of vascular endothelial barrier function. Microvasc Res 2008;76:202-207.
36. Komarova Y, Malik AB. Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu Rev Physiol 2010;72:463-493.
37. Simons PC, Pietromonaco SF, Reczek D, Bretscher A, Elias L. Cterminal threonine phosphorylation activates ERM proteins to link the cell's cortical lipid bilayer to the cytoskeleton. Biochem Biophys Res Commun 1998;253:561-565. (Pubitemid 29039182)
38. Dykes AC, Fultz ME, Norton ML, Wright GL. Microtubule-dependent PKC-alpha localization in A7R5 smooth muscle cells. Am J Physiol Cell Physiol 2003;285:C76-C87. (Pubitemid 36736339)
39. Volkov Y, Long A, McGrath S, Ni Eidhin D, Kelleher D. Crucial importance of PKC-beta(I) in LFA-1-mediated locomotion of activated T cells. Nat Immunol 2001;2:508-514. (Pubitemid 33705852)
40. Lamb RF, Ozanne BW, Roy C, McGarry L, Stipp C, Mangeat P, Jay DG. Essential functions of ezrin in maintenance of cell shape and lamellipodial extension in normal and transformed fibroblasts. Curr Biol 1997;7:682-688. (Pubitemid 27408866)
41. Lopez JP, Turner JR, Philipson LH. Glucose-induced ERM protein activation and translocation regulates insulin secretion. Am J Physiol Endocrinol Metab 2010;299:E772-E785.
42. Jensen PV, Larsson LI. Actin microdomains on endothelial cells: association with CD44, ERM proteins, and signaling molecules during quiescence and wound healing. Histochem Cell Biol 2004;121:361-369. (Pubitemid 38756932)
43. Defacque H, EgebergM, Habermann A, Diakonova M, Roy C, Mangeat P, Voelter W, Marriott G, Pfannstiel J, Faulstich H, et al. Involvement of ezrin/moesin in de novo actin assembly on phagosomal membranes. EMBO J 2000;19:199-212. (Pubitemid 30042702)
44. Poullet P, Gautreau A, Kadare G, Girault JA, Louvard D, Arpin M. Ezrin interacts with focal adhesion kinase and induces its activation independently of cell-matrix adhesion. J Biol Chem 2001;276:37686-37691.
45. Takahashi K, Sasaki T, Mammoto A, Takaishi K, Kameyama T, Tsukita S, Takai Y. Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J Biol Chem 1997;272:23371-23375. (Pubitemid 27392478)
46. Yang HS, Hinds PW. Phosphorylation of ezrin by cyclin-dependent kinase 5 induces the release of Rho GDP dissociation inhibitor to inhibit Rac1 activity in senescent cells. Cancer Res 2006;66:2708-2715.